In short
China's 2025 primary liver cancer guideline (focused on hepatocellular carcinoma) refines early screening with ultrasound plus AFP, stresses MDT-based staging, and standardizes surgery, ablation, TACE, systemic therapy, and liver transplantation pathways.
What this guide covers: Scope and burden · Screening and diagnosis · Staging and MDT · Treatment options · For patients
Scope and burden
Primary liver cancer—mainly hepatocellular carcinoma (HCC)—is among the most common cancers in China and a leading cause of cancer death. The 2025 China guideline (full edition) updates screening, diagnosis, and a multidisciplinary treatment framework.
Screening and diagnosis
High-risk groups (cirrhosis, chronic hepatitis B/C, family history) should be screened every 6 months with liver ultrasound plus serum AFP. Definitive diagnosis combines dynamic contrast imaging and, when needed, biopsy; AFP-L3 and PIVKA-II are useful adjuncts.
Staging and MDT
Tumor burden, liver function (Child-Pugh), and portal pressure guide staging. A multidisciplinary team (MDT) selects among resection, ablation, transarterial chemoembolization (TACE), systematic therapy, and transplantation.
Treatment options
Early disease is potentially curable by surgery or ablation. Intermediate-stage HCC often uses TACE; advanced disease increasingly uses targeted agents plus immunotherapy. Transplant follows established criteria (e.g., Milan) for selected patients.
For patients
China has comprehensive HCC centers offering the full range of therapies. Bring prior imaging and hepatitis status so staging and the right treatment sequence can be planned promptly.
Sources and further reading
One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.
General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.
